ASTRAZENECA PLC reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Cambridge
SEC filing record 1 source field available
Fiscal year end
31 December
ASTRAZENECA PLC has filed 2,050 SEC EDGAR filings since 13 Mar 1995

SEC filing history

Showing 551-575 of 1,000 matching filings.

Per page
25
Current page
23
6-K File 001-11960

SETTLEMENT OF PATENT LITIGATION FOR ULTOMIRIS

Filing date
17 Mar 2022
Reporting date
17 Mar 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

LYNPARZA APPROVED IN US FOR EARLY BREAST CANCER

Filing date
14 Mar 2022
Reporting date
14 Mar 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

UPDATE ON US REVIEW OF FASENRA IN NASAL POLYPS

Filing date
14 Mar 2022
Reporting date
14 Mar 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
09 Mar 2022
Reporting date
09 Mar 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
07 Mar 2022
Reporting date
07 Mar 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
01 Mar 2022
Reporting date
01 Mar 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Mar 2022
Reporting date
01 Mar 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA AND NEURIMMUNE CLOSE DEAL FOR NI006

Filing date
01 Mar 2022
Reporting date
01 Mar 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FILING OF FORM 20-F WITH SEC

Filing date
23 Feb 2022
Reporting date
23 Feb 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
IRANNOTICE File 001-11960

IRANNOTICE

Filing date
22 Feb 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

CHAIR SUCCESSION PLANNING UPDATE AND ANNUAL REPORT

Filing date
22 Feb 2022
Reporting date
22 Feb 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ENHERTU IMPROVES PFS AND OS IN HER2-LOW BC

Filing date
22 Feb 2022
Reporting date
22 Feb 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

SAPHNELO APPROVED IN EU FOR SLE

Filing date
16 Feb 2022
Reporting date
16 Feb 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

LYNPARZA COMBO DELAYS PROGRESSION RISK IN PROSTATE

Filing date
15 Feb 2022
Reporting date
15 Feb 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
11 Feb 2022
Reporting date
11 Feb 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

AZN: FULL YEAR AND Q4 2021 RESULTS

Filing date
10 Feb 2022
Reporting date
10 Feb 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-55247

SC 13G/A filing

Filing date
07 Feb 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-55247

SEC SCHEDULE 13G

Filing date
04 Feb 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Feb 2022
Reporting date
01 Feb 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI IMPROVES SURVIVAL IN BILIARY TRACT CANCER

Filing date
19 Jan 2022
Reporting date
19 Jan 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI COMBO SHOWS UNPRECEDENTED SURVIVAL IN HCC

Filing date
19 Jan 2022
Reporting date
19 Jan 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ENHERTU GRANTED PRIORITY REVIEW FOR BREAST CANCER

Filing date
18 Jan 2022
Reporting date
18 Jan 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA AND NEURIMMUNE SIGN DEAL FOR NI006

Filing date
07 Jan 2022
Reporting date
07 Jan 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TRANSFER OF RIGHTS TO EKLIRA, DUAKLIR COMPLETED

Filing date
05 Jan 2022
Reporting date
05 Jan 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .